Lingzhan Meng

Chinese PLA General Hospital

Papers

1

Total Citations

14

H-Index

1

About

Lingzhan Meng is a leading figure in hepatobiliary surgery, with a focused expertise in minimally invasive techniques for treating hepatocellular carcinoma (HCC). His major contribution lies in rigorously comparing the efficacy and safety of robotic versus laparoscopic liver resection, addressing a critical gap in long-term outcome evidence. In his landmark 2024 study, which has already garnered 14 citations, Meng employed a propensity score-matched retrospective cohort design to evaluate patients undergoing these advanced procedures between 2016 and 2021. This work provides essential, high-quality data that helps surgeons and patients make informed decisions about surgical approaches for HCC. By systematically analyzing perioperative and oncologic outcomes, Meng’s research directly impacts clinical practice, advancing the field toward safer, more effective, and less invasive liver cancer surgery. His dedication to evidence-based surgical innovation positions him as a key contributor to the evolution of robotic hepatobiliary surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Efficacy and safety of robotic versus laparoscopic liver resection for hepatocellular carcinoma: a propensity score-matched retrospective cohort study
14 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Chinese PLA General Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago